Skip to main content
. Author manuscript; available in PMC: 2011 Aug 11.
Published in final edited form as: Am J Transplant. 2006 Aug 4;6(10):2409–2417. doi: 10.1111/j.1600-6143.2006.01495.x

Table 3.

Immunosuppression regimen status and frequency of immunosuppression dosing in living donor renal transplant recipients

Alemtuzumab induction Historical control
No. of recipients 205 47
Daily monotherapy 90 (43.9%) 15 (31.9%)
Spaced-dose monotherapy 87 (42.4%) N/A
Multi-immunosuppressive drug therapy 21* (10.2%) 20 (42.5%)
*

On multiple immunosuppressive drugs (not just tacrolimus monotherapy) because of ACR episodes, a combination of mycophenolate mofetil, prednisone or rapamune were added.